- Research article
- Open Access
Characterization of gana-1, a Caenorhabditis elegans gene encoding a single ortholog of vertebrate α-galactosidase and α-N-acetylgalactosaminidase
- Jana Hujová†1,
- Jakub Sikora†1,
- Robert Dobrovolný†1,
- Helena Poupětová1,
- Jana Ledvinová1,
- Marta Kostrouchová1 and
- Martin Hřebíček1Email author
© Hujová et al; licensee BioMed Central Ltd. 2005
- Received: 13 September 2004
- Accepted: 27 January 2005
- Published: 27 January 2005
Human α-galactosidase A (α-GAL) and α-N-acetylgalactosaminidase (α-NAGA) are presumed to share a common ancestor. Deficiencies of these enzymes cause two well-characterized human lysosomal storage disorders (LSD) – Fabry (α-GAL deficiency) and Schindler (α-NAGA deficiency) diseases. Caenorhabditis elegans was previously shown to be a relevant model organism for several late endosomal/lysosomal membrane proteins associated with LSDs. The aim of this study was to identify and characterize C. elegans orthologs to both human lysosomal luminal proteins α-GAL and α-NAGA.
BlastP searches for orthologs of human α-GAL and α-NAGA revealed a single C. elegans gene (R07B7.11) with homology to both human genes (α-ga lactosidase and α-N-a cetylgalactosaminidase) – gana-1. We cloned and sequenced the complete gana-1 cDNA and elucidated the gene organization.
Phylogenetic analyses and homology modeling of GANA-1 based on the 3D structure of chicken α-NAGA, rice α-GAL and human α-GAL suggest a close evolutionary relationship of GANA-1 to both human α-GAL and α-NAGA.
Both α-GAL and α-NAGA enzymatic activities were detected in C. elegans mixed culture homogenates. However, α-GAL activity on an artificial substrate was completely inhibited by the α-NAGA inhibitor, N-acetyl-D-galactosamine.
A GANA-1:: GFP fusion protein expressed from a transgene, containing the complete gana-1 coding region and 3 kb of its hypothetical promoter, was not detectable under the standard laboratory conditions. The GFP signal was observed solely in a vesicular compartment of coelomocytes of the animals treated with Concanamycin A (CON A) or NH4Cl, agents that increase the pH of the cellular acidic compartment.
Immunofluorescence detection of the fusion protein using polyclonal anti-GFP antibody showed a broader and coarsely granular cytoplasmic expression pattern in body wall muscle cells, intestinal cells, and a vesicular compartment of coelomocytes.
Inhibition of gana-1 by RNA interference resulted in a decrease of both α-GAL and α-NAGA activities measured in mixed stage culture homogenates but did not cause any obvious phenotype.
GANA-1 is a single C. elegans ortholog of both human α-GAL and α-NAGA proteins. Phylogenetic, homology modeling, biochemical and GFP expression analyses support the hypothesis that GANA-1 has dual enzymatic activity and is localized in an acidic cellular compartment.
- Green Fluorescent Protein
- Fabry Disease
- Green Fluorescent Protein Signal
- Green Fluorescent Protein Fusion Protein
- Lysosomal Storage Disorder
Humans have two enzymes with α-galactosidase activity and an acidic pH optimum, α-N-acetylgalactosaminidase (α-NAGA) (previously called α-galactosidase B) and α-galactosidase A (α-GAL). Hereditary deficiency of each of the hydrolases causes a distinct lysosomal storage disorder in humans, Schindler and Fabry diseases, respectively [1, 2].
Early studies suggested that both human enzymes were glycoforms with similar substrate specifities. Purified enzymes had similar physical properties, including subunit molecular mass (~46 kDa), homodimeric structure, and amino acid sequences. However, additional studies showed kinetic, structural, and immunologic differences proving that α-GAL and α-NAGA were products of two different genes [3, 4]. The two genes differed in the number of exons (7 and 9, respectively) and also in the number, placement, and orientation of Alu repeats. Exons 2 – 7 of the α-NAGA gene showed high similarity to the first six exons of α-GAL gene. Because of the remarkable amino acid identity (49%) and similarity (63%) between the two genes and the similar intron placement, Wang  and co-workers suggested that a duplication event occurred during the evolution of both enzymes.
Both enzymes belong to the glycoside hydrolase family 27 clan D . Glycoside hydrolase family 27 clan D orthologs have been identified in a broad spectrum of prokaryotes and eukaryotes, including plants. Members of the family have a highly similar active site and share the same reaction mechanism. The structures of chicken α-NAGA, human α-GAL and rice α-GAL have been determined by X-ray crystallography [7–9]. Chicken and human enzymes have a homodimeric quarternary structure whereas rice α-GAL acts as a monomer. The monomer units are composed of two distinct domains. Domain I contains the active site and adopts a (β/α)8 barrel structure, a domain fold observed commonly in glycosidases. Domain II has eight antiparallel β strands, packed into two β sheets in a β sandwich fold containing a Greek key motif .
Our recent study on degradation of blood group A and B glycolipids in Fabry cells indicated a high residual activity in Fabry cells toward natural substrate glycolipid B-6-2  although α-galactosidase activity was completely absent when measured in vitro by routine procedures using artificial substrates. We proposed that another enzyme, different from α-GAL, contributes in vivo to hydrolysis of α-galactosides. We suggested α-NAGA as the most likely candidate. Human α-NAGA is known to accept α-galactosides albeit with a high Km [11, 12]. Its activity must be inhibited when measuring α-GAL in tissues with high α-NAGA activity .
We investigated the phylogenesis of a single C. elegans α-GA L and α-NA GA ortholog (gana-1) to both human genes. We present evidence suggesting that this gene has indeed evolved from the α-GAL/α-NAGA ancestral gene before the duplication event which resulted in separate α-NAGA and α-GAL genes in higher metazoans. We further performed structural analysis of the GANA-1 3D model acquired by homology modeling. We determined the spatial and temporal expression of the gene in transgenic worms using a translational reporter and examined the effect of RNA interference (RNAi) as a first step in the possible use of C. elegans as a model organism for Schindler and Fabry diseases.
cDNA amplification and sequencing
The complete C. elegans genome [14, 15] contains only one open reading frame, designated gana-1 (R07B7.11) that has sequence similar to human genes encoding α-GAL and α-NAGA. Similar results were obtained from searching the available C. briggsae genome sequence . The gana-1 gene consists of 5 exons and 4 introns and is annotated as an ortholog of human α-NAGA. Several EST clones for this open reading frame (ORF) have been reported and open-reading-frame sequence tag (OST) is present in the Worfdb database . Available public database data are in agreement with our findings.
In our opinion, the phylogenetic analysis provides evidence that the GANA-1 evolved from a common ancestor of α-GAL and α-NAGA enzymes. However, the topology of the tree could also be explained by a loss of the second gene during the evolution of C. elegans. In this case the enzyme found in C. elegans would probably be the ortholog of human α-NAGA and the lost gene would likely be the ortholog of human α-GAL. The likelihood of these two hypotheses depends on functional divergence of duplicated gene products and their dispensability for organism's metabolic pathways .
Residues forming the "N-acetyl recognition loop" in the chicken α-NAGA  (S172, A175, Y176) have the closest contact with the N-acetyl moiety of the ligand. These residues are completely conserved between human and chicken NAGAs, but in human α-GAL serin 172 is replaced by glutamine and alanine 175 is replaced by leucine. The replacements with bulkier residues apparently discriminate between α-GAL and α-NAGA substrates. While NAGAs can accommodate α-galactose and can have some α-GAL activity, GALs do not have α-NAGA activity and are not inhibited by N-acetylgalactosamine. The corresponding residues of GANA-1 in the NAGA recognition loop are S186 and A189 and are characteristic for NAGAs.
Additional File 1: Structure of GANA-1 dimer. The color of the backbone represents differences of amino acids between GANA-1 and chicken NAGA. Blue color represents identical residues and orange stands for non-conservative changes. The colors from cyan to green represent different degrees of conservation. The surface of one monomer unit at the interface area is rendered with colors representing electrostatic potential. N-acetyl-D-galactosamine (inhibitor) is placed in the active site pocket of both monomer units (D-GalNAc arrowhead). K257 arrowhead depicts predicted dimerisation residue. (MPG 8 MB)
Standard bacteria/nematode separation protocol previously used by other authors [22, 23] while evaluating lysosomal enzyme activites is based on sucrose flotation approach. We avoided standard sucrose flotation of worms because we could not exclude unpredictable artifacts caused by this compound, which is known to induce artificial lysosomal storage in eukaryotic cells and to alter lysosomal gene expression at concentrations significantly lower  than those used in flotation protocols.
We found both α-GAL and α-NAGA enzymatic activities in the homogenates from C. elegans N2 strain using 4-methylumbelliferyl (MU) substrates. The α-NAGA activity was dominant over the α-GAL activity. The activity of α-NAGA measured at 37°C was 430 nmol.mg-1.h-1 with MU-α-N-acetylgalactosaminide compared to the activity of α-GAL with MU-α-galactopyranoside of 43 nmol.mg-1.h-1 (about 10% of that of α-NAGA).
In the assay of α-GAL, the degradation of the MU-α-galactopyranoside was inhibited up to 95% in the presence of N-acetyl-D-galactosamine (D-GalNAc), whereas in the presence of D-galactose (D-Gal) the degradation of the same substrate was inhibited up to 75%. In the assay of α-NAGA, the degradation of the MU-α-N-acetylgalactosaminide was inhibited up to 97% by D-GalNAc and up to 90% by D-Gal. No inhibition of α-NAGA and α-GAL activity by D-glucose was observed.
According to published observations in human enzymes, D-GalNAc has no inhibitory effect on α-GAL activity. On the other hand, human α-NAGA activity is inhibited by both, D-GalNAc and D-Gal . The model of GANA-1 predicts only one active site per monomer of the enzyme. If the enzyme had activity toward both substrates, MU-α-D-galactopyranoside and MU-α-N-acetylgalactosaminide, it is to be expected that D-GalNAc and D-Gal would inhibit both activities. The strong inhibitory effect of D-GalNAc on the α-GAL activity, which is not present in human α-GAL, supports the hypothesis that C. elegans has only one enzyme with both α-GAL and α-NAGA activities. Nevertheless, these experiments were not conducted with the pure enzyme and thus do not provide absolute proof of this hypothesis.
α-GAL and α-NAGA activities after gana-1 RNAi. The table shows a proportional parallel decrease of both enzymatic activities (α-GAL and α-NAGA) after gana-1 RNAi compared to controls.
α-GAL (% of control)
α-NAGA (% of control)
α-NAGA/α-GAL (% of control)
Both enzymatic activities were lower in RNAi-treated and control worms cultured on the bacterial strain HT115  compared to a N2 strain cultured on the OP50 strain.
RNAi previously provided sufficient level of inhibition of structural lysosomal proteins for development of abnormal phenotypes in the worm [27, 28]; however, it is apparently not efficient enough for lysosomal catalytic proteins.
Expression of gana-1
To study the expression of gana-1 in C. elegans, we created transgenic worms with a reporter gene containing the entire coding region of gana-1 C-terminally tagged with green fluorescent protein (GFP) under the control of a 3 kb region of the gana-1 hypothetical promoter. The presence of the gana-1::GFP transgene in the worms was confirmed on the level of genomic DNA, cDNA and protein. However, no GFP signal was observed by fluorescence microscopy under the standard laboratory conditions. As Western blotting showed the presence of fusion protein of the expected size (data not shown), we assumed that the absence of the GFP signal was caused by a pH-dependent quenching of GFP fluorescence, which has neutral to alkaline optimum (pH 5.5–12) .
To study the tissue and intracellular distribution of the fusion protein, we resorted to immunofluorescence detection of the transgene product. Immunofluorescence detection of GFP fusion protein showed a specific and coarsely granular cytoplasmic pattern of fusion protein expression. This transgene product was limited to body wall muscle cells (30% of population) (Figure 5A, Additional file 2) or found in a broader tissue distribution that included body wall muscle cells, intestinal cells and coelomocytes (3–5% of population) (Figure 5B, Additional file 3).
To confirm that the absence of the GFP signal was due to the quenching of fluorescence by low pH in the acidic cellular compartment, we used two agents specifically alkalizing acidic cellular compartment [33, 34] to enhance the GFP emission. Soaking of gana-1::GFP transgenic animals in NH4Cl or CON A resulted in a distinct GFP signal in a vesicular compartment of endocytically active coelomocytes in a small proportion of worms (3–5% of population). The GFP signal intensity was dependent on the time of incubation and the concentration of the alkalizing agent used. The first visible GFP signal was observed after 8 hour incubation in 100 mM NH4Cl and within 2 hours of incubation in 50 nM CON A. Lower concentrations of both NH4Cl and CON A did not result in visible GFP signal even after prolonged incubation of up to 24 hours. The reappearance of the GFP signal after treatment of the worms with compounds increasing the acidic compartment pH indirectly confirms lysosomal localization of the fusion protein. The GFP signal in coelomocytes had the same coarsely granular pattern as that observed after immunostaining.
Limited access of alkalizing agents to the tissues can explain the differences between the results of immunofluorescence and alkalization studies.
Our findings showed that gana-1 is the only ortholog of human α-NAGA and α-GAL in C. elegans. Based on phylogenetic and homology modeling analyses we speculate that GANA-1 most probably developed from a hypothetical ancestral gene before the duplication event which gave rise to separate α-NAGA and α-GAL genes.
We also speculate that gana-1 gene product has both α-NAGA and α-GAL activities as detected in C. elegans homogenates. Importantly, both activities in the worm were inhibited by D-galactose and N-acetyl-D-galactosamine, which is a specific inhibitor of human α-NAGA and does not inhibit α-GAL.
The GANA-1::GFP fusion protein had a pattern of distribution that is compatible with lysosomal subcellular localization. The lysosomal localization of the fusion protein was also supported by pH sensitive fluorescence of GFP that was detectable only after alkalization of the acidic cellular compartment.
Not suprisingly, RNAi of gana-1 yielded no abnormal morphological phenotypes, most likely because it did not provide sufficient knockdown of enzymatic activities, necessary for development of lysosomal storage as observed in human pathology states. Nevertheless, gana-1 RNAi resulted in a partial decrease of both enzymatic activities supporting the notion that this gene encodes both of them.
It is possible that a deletion allele of gana-1 may provide more insight into the function of gana-1 and efforts are underway to isolate such alleles. Deletion alleles of lysosomal hydrolases may serve as valuable models of human lysosomal storage disorders.
C. elegans methods, strains and nomeclature
The wild type Bristol N2 strain was used for all experiments and was handled under standard laboratory conditions as described previously . Standard methods were used for DNA microinjection  and dsRNA synthesis and microinjection . Nomenclature is in agreement with available Genetic Nomenclature for Caenorhabditis elegans  and has been approved prior to manuscript submission.
Wormbase (2002–2004 versions and freeze versions [15, 38, 39]) databases were repeatedly searched for human α-GAL and α-NAGA orthologs using the BLASTP  program set at default values. Amino acid sequences of human lysosomal α-GAL and α-NAGA (acc. no. NP_000160 and acc. no. NP_000253 ) were used as query sequences.
cDNA amplification and sequencing
Total RNA was isolated from mixed stages of N2 cultures  and reverse transcribed with an oligodT-T7 (5'-AATACGACTCACTATAG) primer and Superscript reverse transcriptase (Invitrogen). The entire coding region of R07B7.11 was PCR amplified in two overlapping PCR products, with intragenic primers designed according to available Wormbase  and Worfdb  data. SL1 primer (5'GGTTTAATTACCCAAGTTTGAG) and SL2 primer (5'GGTTTTAACCCAGTTACTCAAG)  together with gene specific primer (5'ATCCTGATTAATTTTAATTGC) were used to amplify 942 bp of the 5' part of the cDNA and to evaluate the mode of trans splicing; the 1142 bp fragment of the 3' end of cDNA was amplified with T7 primer and a gene specific primer (5'CTTAAGTTTGGAATTTATGAA). The dominant PCR products were cloned with TOPO TA cloning kit (Invitrogen) into the pCR 2.1 vector. Positive clones were sequenced using the Li-Cor automated fluorescent sequencer and sequences were aligned with R07B7 reference cosmid sequence in the AlignIR software (Li-Cor) to evaluate splicing boundaries and overall gene organization.
Multiple alignment and phylogenetic analyses
Confirmed or predicted amino acid sequences of melibiase family members  representing plant, unicellular, and animal kingdoms were aligned using ClustalW algorithm  and Blosum62 matrix. The SwissProt/TrEMBL  accesion code and source organism of the sequences are depicted in Figure 2. The sequence alignment was used for phylogenetic analysis with the software package PHYLIP . The phylogenetic tree is based on 100 bootstraped input alignments and was constructed by maximum likelihood method with Jones-Taylor-Thornton matrix model . Sequence identities between species were calculated without signal sequence in EMBOSS by Needleman-Wunsch global alignment algorithm with Blosum62 matrix, gap penalty – 10 and gap extension penalty – 0.5 [8, 48, 49]. Signal peptides were predicted at the SignalP server  both by algorithms using neural networks and Hidden Markov Models. The results were compared to known signal sequences. The differences between signal peptides predicted by the algorithms are depicted in Figure 2.
The 3D model of GANA-1 is based on the X-ray structure of chicken α-NAGA, rice α-GAL and human α-GAL (PDB codes 1ktcA, 1uas and 1r47, respectively) [7–9, 51]. The model was created using the automated homology modeling server SwissModel with structure refinement and model evaluation in the DeepView program . The print quality figures (Figure 4) and animations (Additional file 1) were ray traced using PovRay software package .
Transgenic GFP expression
The entire coding region of the gana-1 gene, including 3 kb of its 5'upstream sequence, was amplified from N2 genomic DNA through a nested PCR reaction using DyNAzyme EXT™ PCR system (Finnzymes) and two pairs of primers: the external pair (5'GTGAGAGTGGGGAGATAGAA and 5'TCAATTTGCTTGAGGTACATA) and the internal primers, with overhangs containing SphI and SalI restriction sites respectively (5'ACATGCATGCAACTTTCACAGGAACACAAC and 5'CGACGTCGACAATTGAACTCTATTGGTTCTCAA). The amplified DNA fragment (4709 bp) was cloned using TOPO-XL cloning kit (Invitrogen) into the pCR-XL-TOPO vector. The SphI and SalI gana-1 restriction fragment was recloned into the GFP reporter vector pPD95.67 (supplied by A. Fire, Stanford University). The in-frame nature of the insert was confirmed by sequencing. The green fluorescent protein (GFP) fusion construct pJH3 (50 ng/μl) and pRF4 plasmid (50 ng/μl) used as the dominant marker were co-injected into the gonads of young adult N2 worms. Transgenic animals were screened for GFP signal. Nikon Eclipse E800 with C1 confocal module and 488 nm and 543 nm lasers and differential interference contrast (DIC) optics was used for specimen examination. EZ-C1 software (Nikon) was used for picture analysis and 3D rendering (Additional Files 2, 3).
Alkalization of acidic cell compartment
Mixed stage pJH3 and N2 (control) cultures were harvested from NGM OP50 plates and washed with water. Worms were pelleted by centrifugation (max. 1000 RPM, 2 min.) between the washes. Worms were treated with either one of two agents (NH4Cl, concanamycin A – CON A) [33, 34], that are known to specifically increase pH in the cellular acidic compartment. For the NH4Cl method, animals were suspended in 0, 10, 25, 50, 75 and 100 mM aqueous solutions of NH4Cl. Small aliquots of worms were examined after 30 min, 2, 4, 6, 8 and 24 hours. For CON A, animals were suspended in 0, 10, 20, 50, 100, 150, 200 nM solutions of CON A in aqueous media. Small aliquots of worms were examined after 1, 3, 6 and 24 hours.
Microscopical examination was performed as described above.
The fixation and immunofluorescence staining procedures were based on the approaches of Nonet et al. . Mixed stage N2 cultures were harvested from NGM OP50 plates and washed thoroughly in M9 buffer to remove intestinal bacteria. Worms were pelleted by centrifugation (1000 RPM, 2 min.) between the washes. Worms were fixed overnight in 4% paraformaldehyde in 100 mM sodium/potassium phosphate buffer. Afterwards the pellets were washed three times in 1 × PBS, and incubated in 1% Triton X-100, 100 mM Tris (pH 7.0), 1% β-Mercaptoethanol overnight at 37°C to reduce the cuticle. After 5 washes in 1 × PBS, the worms were incubated for 5 hours in 900 U/ml collagenase type IV (Sigma) diluted in Krebs-Ringer solution (119 mM NaCl, 25 mM NaHCO3, 11.1 mM glucose, 1.6 mM CaCl2·H2O, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4·7H2O, pH 7.4). The reduction/digestion step was performed twice. Pellets were washed 3 times with 1 × PBS and stored for further processing in AbA buffer (1 × PBS, 0.1% Triton X-100, 1% BSA, 0.05% NaN3). AbA buffer was used for antibody dilution. Primary antibody (polyclonal rabbit anti-GFP IgG (Abcam)) was diluted 1:500. Secondary antibody (goat anti-rabbit IgG Alexa Fluor 488 labeled (Molecular Probes)) was diluted 1:1000. Both incubations were performed overnight at room temperature, with AbB buffer (1 × PBS, 0.1% Triton X-100, 0.1% BSA, 0.05% NaN3) washes in between.
Nuclei were counterstained with SYTOX orange (Molecular Probes) and the microscopic evaluation was performed as described above.
Mixed stage pJH3 and N2 cultures were harvested from NGM OP50 plates. Worms were homogenized by sonication and the concentration of protein was measured by the Hartree method . The proteins (equivalent of 25–50 μg of protein per lane) were separated by SDS-PAGE gradient gel (4% to 20% polyacrylamide) and transferred onto nitrocellulose membrane by semi-dry blotting. The membrane was treated according to a common Western blotting protocol with chemiluminiscence detection (SuperSignal, West Pico) . Rabbit polyclonal anti-GFP IgG (Abcam, dilution 1:5000) was used as the primary antibody, the secondary antibody was goat anti-rabbit IgG/Px (Pierce, diluted 1:20 000).
RNA mediated interference
The PCR product containing the entire gana-1 cDNA was cloned into pCRII-TOPO vector (Invitrogen) and L4440 double promoter vector for microinjection and feeding RNAi respectively. In-vitro transcription employing T7 and SP6 RNA polymerases (Promega) was used to generate antisense single stranded RNA molecules, which were annealed to generate double stranded RNA (dsRNA). dsRNA was microinjected into N2 worms which were fed on HT115 E. coli strain carrying L4440 plasmid with gana-1 insert. The F1 and early F2 progeny was screened for morphological phenotypes. N2 worms microinjected with water and fed on HT115 E. coli transformed with L4440 vector without insert were used as a control. 5–7 worms were microinjected both with dsRNA and water in each of 4 separate experiments, single worm progeny reaching 110–150 individuals.
Determination of α-GAL and α-NAGA and β-hexosaminidase activities
Prior to all activity measurements worms were washed from culture plates and repeatedly (6 times) washed and centrifuged in M9 buffer and finally pelleted by centrifugation. 4-methylumbelliferyl (MU)-α-D-N-acetylgalactosaminide (1 mM), 4-MU-α-D-galactopyranoside and 4-MU-β-D-glucopyranoside in theMcIlvaine buffer (0.1 M citrate/0.2 M phosphate buffer at acidic pH) were used as enzyme substrates. Reaction mixtures (sample and enzyme substrate) were incubated at 37°C and reactions were stopped by 600 μl of 0.2 M glycine/ NaOH buffer (pH 10.6) [13, 57]. Fluorescence signal of the 4-methylumbelliferone was measured on the luminiscence spectrofotometer LS 50B (Perkin Elmer) (emission 365 nm and excitation 448 nm). Inhibitors (N-acetyl-D-galactosamine, D-galactose and D-glucose) were used in 0.1 M final concentration. All measurements were performed in doublets.
This work was supported by a grant 303/02/1324 from the Czech Science Foundation and partially also from grant VZ111100003 from Ministry of Education of the Czech Republic (institutional support).
We would like to thank Michael Krause, Ph.D. (NIDDK) and Zdeněk Kostrouch, Ph.D. (Institute of Inherited Metabolic Disorders) for critical reading of the manuscript and Eva Brožová, Kateřina Šimečková, Hana Prouzová and Lenka Brtvová (Institute of Inherited Metabolic Disorders) for technical advice and assistance.
- Desnick RJ, Schindler D: α-N-Acetylgalactosaminidase Deficiency: Schindler Disease. The Metabolic & Molecular Bases of Inherited Disease. Edited by: Scriver CR, Beaudet AL, Sly WS and Valle D. 2001, New York, McGraw-Hill Companies, Inc., 3: 3483-3506. 8thGoogle Scholar
- Desnick RJ, Ioannou YA, Eng CM: α-Galactosidase A Deficiency: Fabry Disease. The Metabolic & Molecular Bases of Inherited Disease. Edited by: Scriver CR, Beaudet AL, Sly WS and Valle D. 2001, New York, McGraw-Hill Companies, Inc., 3: 3733-3774. 8thGoogle Scholar
- Dean KJ, Sung SS, Sweeley CC: The identification of alpha-galactosidase B from human liver as an alpha-N-acetylgalactosaminidase. Biochem Biophys Res Commun. 1977, 77: 1411-1417.View ArticlePubMedGoogle Scholar
- Schram AW, Hamers MN, Brouwer-Kelder B, Donker-Koopman WE, Tager JM: Enzymological properties and immunological characterization of alpha-galactosidase isoenzymes from normal and Fabry human liver. Biochim Biophys Acta. 1977, 482: 125-137.View ArticlePubMedGoogle Scholar
- Wang AM, Desnick RJ: Structural organization and complete sequence of the human alpha-N-acetylgalactosaminidase gene: homology with the alpha-galactosidase A gene provides evidence for evolution from a common ancestral gene. Genomics. 1991, 10: 133-142. 10.1016/0888-7543(91)90493-X.View ArticlePubMedGoogle Scholar
- Henrissat B, Davies G: Structural and sequence-based classification of glycoside hydrolases. Curr Opin Struct Biol. 1997, 7: 637-644. 10.1016/S0959-440X(97)80072-3.View ArticlePubMedGoogle Scholar
- Garman SC, Hannick L, Zhu A, Garboczi DN: The 1.9 A structure of alpha-N-acetylgalactosaminidase: molecular basis of glycosidase deficiency diseases. Structure (Camb). 2002, 10: 425-434. 10.1016/S0969-2126(02)00726-8.View ArticleGoogle Scholar
- Garman SC, Garboczi DN: The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol. 2004, 337: 319-335. 10.1016/j.jmb.2004.01.035.View ArticlePubMedGoogle Scholar
- Fujimoto Z, Kaneko S, Momma M, Kobayashi H, Mizuno H: Crystal structure of rice alpha-galactosidase complexed with D-galactose. J Biol Chem. 2003, 278: 20313-20318. 10.1074/jbc.M302292200.View ArticlePubMedGoogle Scholar
- Asfaw B, Ledvinova J, Dobrovolny R, Bakker HD, Desnick RJ, van Diggelen OP, de Jong JG, Kanzaki T, Chabas A, Maire I, Conzelmann E, Schindler D: Defects in degradation of blood group A and B glycosphingolipids in Schindler and Fabry diseases. J Lipid Res. 2002, 43: 1096-1104. 10.1194/jlr.M100423-JLR200.View ArticlePubMedGoogle Scholar
- Dean KJ, Sweeley CC: Studies on human liver alpha-galactosidases. II. Purification and enzymatic properties of alpha-galactosidase B (alpha-N-acetylgalactosaminidase). J Biol Chem. 1979, 254: 10001-10005.PubMedGoogle Scholar
- Schram AW, Hamers MN, Tager JM: The identity of alpha-galactosidase B from liver. Adv Exp Med Biol. 1978, 101: 525-529.View ArticlePubMedGoogle Scholar
- Mayes JS, Scheerer JB, Sifers RN, Donaldson ML: Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. Clin Chim Acta. 1981, 112: 247-251. 10.1016/0009-8981(81)90384-3.View ArticlePubMedGoogle Scholar
- Genome sequence of the nematode C. elegans: a platform for investigating biology. The C. elegans Sequencing Consortium. Science. 1998, 282: 2012-2018. 10.1126/science.282.5396.2012.Google Scholar
- Wormbase. [http://www.wormbase.org/]
- The C. elegans ORFeome cloning project. [http://worfdb.dfci.harvard.edu/]
- Krause M: Caenorhabditis elegans: Modern Biological Analysis of an Organism. Edited by: Epstein HF and Shakes DC. 1995, San Diego, Academic Press, Inc., 48: 483-512. Transcription and Translation, 1st, Methods in Cell BiologyView ArticleGoogle Scholar
- Nimmo R, Woollard A: Widespread organisation of C. elegans genes into operons: fact or function?. Bioessays. 2002, 24: 983-987. 10.1002/bies.10181.View ArticlePubMedGoogle Scholar
- Blumenthal T, Gleason KS: Caenorhabditis elegans operons: form and function. Nat Rev Genet. 2003, 4: 112-120. 10.1038/nrg995.View ArticlePubMedGoogle Scholar
- Blom D, Speijer D, Linthorst GE, Donker-Koopman WG, Strijland A, Aerts JM: Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA. Am J Hum Genet. 2003, 72: 23-31. 10.1086/345309.PubMed CentralView ArticlePubMedGoogle Scholar
- Nadeau JH, Sankoff D: Comparable rates of gene loss and functional divergence after genome duplications early in vertebrate evolution. Genetics. 1997, 147: 1259-1266.PubMed CentralPubMedGoogle Scholar
- Sarkis GJ, Kurpiewski MR, Ashcom JD, Jen-Jacobson L, Jacobson LA: Proteases of the nematode Caenorhabditis elegans. Arch Biochem Biophys. 1988, 261: 80-90. 10.1016/0003-9861(88)90106-3.View ArticlePubMedGoogle Scholar
- Sebastiano M, D'Alessio M, Bazzicalupo P: Beta-glucuronidase mutants of the nematode Caenorhabditis elegans. Genetics. 1986, 112: 459-468.PubMed CentralPubMedGoogle Scholar
- Karageorgos LE, Isaac EL, Brooks DA, Ravenscroft EM, Davey R, Hopwood JJ, Meikle PJ: Lysosomal biogenesis in lysosomal storage disorders. Exp Cell Res. 1997, 234: 85-97. 10.1006/excr.1997.3581.View ArticlePubMedGoogle Scholar
- Conzelmann E, Sandhoff K: Glycolipid and glycoprotein degradation. Adv Enzymol Relat Areas Mol Biol. 1987, 60: 89-216.PubMedGoogle Scholar
- Kamath RS, Martinez-Campos M, Zipperlen P, Fraser AG, Ahringer J: Effectiveness of specific RNA-mediated interference through ingested double-stranded RNA in Caenorhabditis elegans. Genome Biol. 2000, 2:Google Scholar
- Kostich M, Fire A, Fambrough DM: Identification and molecular-genetic characterization of a LAMP/CD68-like protein from Caenorhabditis elegans. J Cell Sci. 2000, 113: 2595-2606.PubMedGoogle Scholar
- Fares H, Greenwald I: Regulation of endocytosis by CUP-5, the Caenorhabditis elegans mucolipin-1 homolog. Nat Genet. 2001, 28: 64-68. 10.1038/88281.PubMedGoogle Scholar
- Kneen M, Farinas J, Li Y, Verkman AS: Green fluorescent protein as a noninvasive intracellular pH indicator. Biophys J. 1998, 74: 1591-1599.PubMed CentralView ArticlePubMedGoogle Scholar
- Mello C, Fire A: DNA transformation. Caenorhabditis elegans: Modern Biological Analysis of an Organism. Edited by: Epstein HF and Shakes DC. 1995, San Diego, Academic Press, 48: 451-481. 1stView ArticleGoogle Scholar
- Stinchcomb DT, Shaw JE, Carr SH, Hirsh D: Extrachromosomal DNA transformation of Caenorhabditis elegans. Mol Cell Biol. 1985, 5: 3484-3496.PubMed CentralView ArticlePubMedGoogle Scholar
- Clokey GV, Jacobson LA: The autofluorescent "lipofuscin granules" in the intestinal cells of Caenorhabditis elegans are secondary lysosomes. Mech Ageing Dev. 1986, 35: 79-94. 10.1016/0047-6374(86)90068-0.View ArticlePubMedGoogle Scholar
- Poole B, Ohkuma S: Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J Cell Biol. 1981, 90: 665-669. 10.1083/jcb.90.3.665.View ArticlePubMedGoogle Scholar
- Demaurex N: pH Homeostasis of cellular organelles. News Physiol Sci. 2002, 17: 1-5.PubMedGoogle Scholar
- Brenner S: The genetics of Caenorhabditis elegans. Genetics. 1974, 77: 71-94.PubMed CentralPubMedGoogle Scholar
- Mello CC, Kramer JM, Stinchcomb D, Ambros V: Efficient gene transfer in C.elegans: extrachromosomal maintenance and integration of transforming sequences. Embo J. 1991, 10: 3959-3970.PubMed CentralPubMedGoogle Scholar
- Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998, 391: 806-811. 10.1038/35888.View ArticlePubMedGoogle Scholar
- WormBase Release WS100. [http://ws100.wormbase.org]
- WormBase Release WS110. [http://ws110.wormbase.org]
- Wormbase BLAST or BLAT Search. [http://www.wormbase.org/db/searches/blat]
- GenBank. [http://www.ncbi.nlm.nih.gov/Genbank/index.html]
- Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987, 162: 156-159. 10.1016/0003-2697(87)90021-2.View ArticlePubMedGoogle Scholar
- Protein families database of alignments and HMMs. [http://www.sanger.ac.uk/Software/Pfam]
- Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22: 4673-4680.PubMed CentralView ArticlePubMedGoogle Scholar
- Swiss-Prot / TrEMBL database. [http://www.expasy.org/sprot/]
- Felsenstein J: PHYLIP - Phylogeny Inference Package (Version 3.2). Cladistics. 1988, 5: 164-166.Google Scholar
- Felsenstein J: Confidence-Limits on Phylogenies - an Approach Using the Bootstrap. Evolution. 1985, 39: 783-791.View ArticleGoogle Scholar
- Needleman SB, Wunsch CD: A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol. 1970, 48: 443-453. 10.1016/0022-2836(70)90057-4.View ArticlePubMedGoogle Scholar
- Rice P, Longden I, Bleasby A: EMBOSS: The European molecular biology open software suite. Trends in Genetics. 2000, 16: 276-277. 10.1016/S0168-9525(00)02024-2.View ArticlePubMedGoogle Scholar
- Bendtsen JD, Nielsen H, von Heijne G, Brunak S: Improved prediction of signal peptides: SignalP 3.0. J Mol Biol. 2004, 340: 783-795. 10.1016/j.jmb.2004.05.028.View ArticlePubMedGoogle Scholar
- PDB - Protein Data Bank. [http://www.rcsb.org/pdb/]
- Guex N, Peitsch MC: SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1997, 18: 2714-2723.View ArticlePubMedGoogle Scholar
- PovRay software. [http://www.povray.org/]
- Nonet ML, Grundahl K, Meyer BJ, Rand JB: Synaptic function is impaired but not eliminated in C. elegans mutants lacking synaptotagmin. Cell. 1993, 73: 1291-1305. 10.1016/0092-8674(93)90357-V.View ArticlePubMedGoogle Scholar
- Hartree EF: Determination of protein: a modification of the Lowry method that gives a linear photometric response. Anal Biochem. 1972, 48: 422-427. 10.1016/0003-2697(72)90094-2.View ArticlePubMedGoogle Scholar
- Gallagher S, Winston SE, Fuller SA, Hurrell JGR: Analysis of Proteins. Current Protocols in Molecular Biology. Edited by: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA and Struhl K. 1997, Hoboken, John Wiley & Sons, Inc., 2: 10.8-1stGoogle Scholar
- Wenger DA, Williams C: Screening for Lysosomal Disorders. Techniques in Diagnostic Human Biochemical Genetics: A Laboratory Manual. Edited by: Hommes FA. 1991, New York, Wiley-Liss, Inc., 587-617. 1stGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.